Introduction
Chronic lymphocytic leukemia (CLL) is accompanied by a complex immune dysregulation, characterized by phenotypical and functional alterations of different host immune components. An increased number of circulating T cells in patients with CLL was observed for the first time more than 40 years ago (1) , but the phenotypical abnormalities and functional defects are still under investigation (2) (3) (4) . T regulatory cells (Treg) are increased in patients with CLL (5) . NK cells are also increased and display a defective cytotoxic activity (6, 7) .
Lenalidomide is an immunomodulatory agent which exerts both direct antitumor effect and pleiotropic activity on the immune system, normalizing CD3 + T-cell and Treg numbers in vivo (8, 9) , promoting antigen-specific T-cell activation, enhancing NK-cell activity and monocyte antibody-dependent cell cytotoxicity (ADCC) (10) , and restoring immunological synapse formation (2) .
Single-agent lenalidomide is active in patients with relapsed or refractory CLL (11, 12) .
In vitro, lenalidomide shows synergism with the anti-CD20 monoclonal antibody (mAb) rituximab by enhancing its CLL cell killing via NK cell-and monocyte-mediated ADCC (10) . Our group evaluated combined rituximab and lenalidomide therapy in a phase II trial for patients with recurrent CLL, showing improvements in the quality and duration of responses when compared to lenalidomide monotherapy. Moreover, the addition of rituximab was accompanied by a decrease in the incidence and severity of lenalidomide-associated tumor flare reaction (TFR) and tumor lysis syndrome (TLS) (13) .
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Author Manuscript Published OnlineFirst on January 5, 2016; DOI: 10.1158/1078-0432.CCR- Ofatumumab is a type I fully human mAb that binds to a distinct epitope on CD20 (14) , and has clinical activity in patients with refractory CLL (15, 16) .
In the present study, we determined the activity and tolerability of combined ofatumumab and lenalidomide for the treatment of relapsed or refractory CLL. We also conducted correlative biological studies to investigate whether immune system and tumor microenvironment characteristics, such as circulating T-and NK-cell number and function, and plasma levels of chemokines, cytokines, and angiogenic factors could be correlated with the response to treatment or could be modulated during the course of the therapy.
Materials and Methods

Patients
Patients with relapsed or refractory CLL were enrolled in a phase II study of combined ofatumumab and lenalidomide. The eligibility criteria included a prior exposure to purine analog-based therapy. Refractory disease was defined as no response to or progression of disease within 6 months from the most recent anti-leukemia therapy (17, 18) . A complete list of inclusion and exclusion criteria is presented in Supplementary Ofatumumab was administered intravenously at a dose of 300 mg on day 1, and 1000 mg on days 8, 15 and 22 during course 1, 1000 mg on day 1 during courses 3-6, and on day 1 once every other course during courses 7-24. The patients self-administered lenalidomide 10 mg daily, orally, starting on day 9 of course 1. Each treatment course lasted 28 days. The planned treatment duration was 24 courses. However, patients who experienced a sustained partial response (PR) or complete response (CR) were allowed to continue treatment with lenalidomide monotherapy indefinitely. Patients were discontinued from the study if progression of disease or unacceptable toxicity were documented at any time. Treatment schema is depicted in Supplementary Figure 1 .
TLS prophylaxis with allopurinol 300 mg daily was prescribed during the first 14 days of therapy. The use of granulocyte colony-stimulating factor (G-CSF) was allowed according to the American Society of Clinical Oncology guidelines (19) . No antiinfectious, DVT, or TFR prophylaxis was mandated based on our previous experience with lenalidomide in the treatment of CLL.
Response and toxicity evaluation
Response was evaluated after courses 3 and 6, then every 6 courses thereafter. The clinical response to therapy was defined as the best response sustained for ≥2 courses at any time during treatment, and assessed according to the 2008 International Workshop on CLL (IWCLL) criteria (17) . Four-color flow cytometry was also performed on BM aspirates to assess minimal residual disease (MRD). Computed tomography scans were not mandated for response assessment, and were used when clinically indicated according to the treating physician. Patients deemed candidate for stem cell transplant (SCT) were transitioned to this procedure according to the principle of 
T and NK cell subset distribution
The absolute numbers of total (CD3 + 
T cell functional assay
T-cell cytotoxicity and cytokine production was assessed on 15 patients at baseline and at the beginning of courses 3 and 6, and on 3 HD. We pre-incubated PBMC alone (negative control) or with CD3/CD28 magnetic beads (Invitrogen, USA) for 6 hours at 
NK cell functional assay
NK cell cytotoxicity and cytokine production was assessed on 15 patients at baseline and at the beginning of courses 3 and 6, and on 3 HD. PBMC were pre-incubated alone 
Angiogenic factors and plasma cytokines quantification
Plasma levels of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), Trombospondin-1 and IFNγ were measured at baseline (n=32), and at the beginning of course 3 (n=30), 6 (n=23), 9 (n=17), and 12 (n=13). Chemokine (C-C motif) ligand 2, 3 and 4 (CCL2, CCL3 and CCL4), TNFα, interferon alpha2 (IFNα2), and interleukin-12p70 (IL-12p70) plasma levels were evaluated in 22 patients at baseline and at the beginning of course 3. Samples were analyzed with multiplexed bead suspension arrays (MBAs; Millipore) according to the manufacturer's instructions and as previously described (12) . MBAs were analyzed using a Luminex 200 machine and data were organized and analyzed using 3.1 xPONENT software (Luminex).
Study end points and statistical analysis
The primary end point of this study was the overall response rate (ORR). Differences in the response rates according to pretreatment characteristics were evaluated using a two-tailed Fisher's exact test. The study secondary objective was tolerance. Stopping rule for toxicity defined excessive toxicity as grade >2 non-hematological adverse events observed in ≥50% of patients. Additional study objectives included the progression-free survival (PFS) duration, which was defined as the time from the start of therapy to death, disease progression, or initiation of the next therapy, and the overall survival (OS) duration, defined as time from the start of therapy to death from any cause. The PFS and OS durations were calculated using Kaplan-Meier estimates, and different groups of patients were compared using the log-rank test. GraphPad Prism (version 6.05 for Windows, GraphPad Software, La Jolla, CA).
Results
Patients
Between January 2010 and January 2011, 36 patients were enrolled in this study. Two patients are not evaluable: one had concomitant myelodysplastic syndrome and one withdrew consent before the start of treatment. The remaining 34 patients were included in the analyses. Patients' pre-treatment characteristics are summarized in Table 1 . months, and the time to MRD-negativity was 12, 18, and 24 months, respectively. None of these patients were fludarabine-refractory or had del17p.
Supplementary Table 3 shows different rates of response according to pre-treatment characteristics. A β2-m level ≥4 mg/dl, more than 3 lines of prior treatment and fludarabine-refractoriness were associated with a lower CR rate (CRR). Fludarabinerefractoriness was also associated with a lower ORR. Patients with del17p showed a trend toward a lower CRR, but this difference was only of borderline significance, possibly because of the small number of patients. Finally, patients receiving an average daily lenalidomide dose of ≥5 mg showed a trend toward superior response rates, but this was not statistically significant (ORR 80% vs. 61%).
Progression-free survival. The estimated median PFS duration was 16 months (95% CI 6-26 months) for the entire study population, and 25 months (95% CI 16-34 months) for the 24 responders ( Figure 1A ). Patients with del17p had significantly shorter PFS durations than those with other cytogenetic abnormalities (5 vs. 27 months, p=0.001) ( Figure 1B) . Similarly, the estimated median PFS duration was shorter for patients with fludarabine-refractory disease (5 vs. 28 months, p<0.0001) and patients who had not responded to their last treatment before entering the study (5 vs. 22 months, p=0.003) ( Figures 1C and 1D) . Interestingly, responses to ofatumumab and lenalidomide were more durable than those to prior therapies in 15 patients (44%). Moreover, 4 of the 10 patients who were refractory to their last treatment experienced long-lasting responses (15, 16, 19 and 27 months) to this combination ( Figure 1E ). Of the 3 patients who achieved MRD-negative CR, two discontinued therapy while in remission because of toxicity after 16 and 22 months, and further maintained the remission for additional 13
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Safety
Overall, 574 courses of therapy were administered during the study period, with a median of 10 courses per patient (range 2-65). The average daily dose of lenalidomide was 5.3 mg for the entire study cohort. It was higher in patients younger than 65 years than in those 65 years of age or older (6.6 mg vs. 4.1 mg, p<0.0001). There was no correlation between the average daily dose of lenalidomide and serum creatinine level.
Median daily dose was ≤2.5 mg in 179 (31%), 5 mg in 226 (40%), 7.5 mg in 12 (2%), and 10 mg in 157 (27%) patient-courses.
One patient developed a G3 infusion reaction at the time of the first dose of ofatumumab. Other grade 3 and 4 hematologic and non-hematologic toxicities observed during treatment are summarized in Table 2 . We observed no grade 3 or 4 TFR or TLS.
As expected, the most common hematologic toxicity was neutropenia, which was documented in 28 (82%) patients and 104 (18%) patient-courses. G-CSF was administered 37 times in 19 patients (56%). Treatment was temporarily interrupted due to neutropenia in 35 instances in 19 patients (56%).
The most frequent infectious complication was pneumonia, with 11 episodes observed in 8 (24%) patients. Neutropenic fever occurred in 3 (9%) patients during the study 
Chemokines and cytokines.
We have previously shown that during lenalidomide treatment patients who respond to therapy have decreased circulating levels of CCL3 and CCL4, compared to NR patients (24) . In this series of patients, we evaluated a broader number of circulating chemokines/cytokines before and during treatment. 
Discussion
Treatment regimens that are devoid of conventional cytotoxic agents are increasingly being developed for patients with CLL, both as initial therapy and as salvage treatment.
The immunomodulatory properties of lenalidomide, combined with the reported activity of ofatumumab in patients with relapsed or refractory CLL, prompted us to evaluate the clinical activity of these two agents in combination and to perform correlative studies to measure the associated changes in T and NK cell number and function, and in circulating chemokines, cytokines and angiogenic factors.
Initial studies exploring the activity of singe-agent lenalidomide in relapsed or refractory CLL showed an ORR of 32-47% (CR 7-9%, PR 25-38%) (11, 12) . In the present study, In our trial, lenalidomide was given continuously until progression or development of unacceptable toxicity. The majority of patients (24, 70%) could not complete the planned 24 months of treatment, however, the duration of response was heterogeneous and several long-lasting responses (11 patients, 32%, >2 years; 6 patients, 18%, >3 years) were achieved.
We observed that the quality of responses (SD vs. PR vs. CR) can improve with time during therapy, and interestingly, the three patients who achieved MRD negativity did so after one year of therapy, confirming a different kinetic of response as compared to This regimen was relatively well tolerated. We did not observe any episode of severe TLS or TFR, which confirms our prior observation that administering anti-CD20 mAb before introducing lenalidomide is an effective strategy to limit these complications.
About half of the patients experienced grade 4 neutropenia, similarly to our previous experience with lenalidomide in association with rituximab. Although episodes of pneumonia and fever appeared to be more frequent in this study (24% and 18%, respectively) compared to our previous study with lenalidomide and rituximab (15% and 13%, respectively), the small patient number limits this comparison. Since the lenalidomide dose was adjusted during treatment according to the toxicities observed, reporting the maximum tolerated dose may not reflect the dose actually delivered for the entire treatment duration. We therefore reported the average dose of lenalidomide (5.3 mg). It was significantly higher in patients younger than 65 years than in those older than 65 years. Nevertheless, the difference in ORR between patients receiving an average daily lenalidomide dose of <5 mg and those receiving ≥5 mg did not reach the statistical significance. Our finding confirms previously published data that identified lenalidomide dosing for patients with CLL to be lower than that tolerated by patients with multiple myeloma and non-Hodgkin lymphomas.
The reported incidence of VTE in patients with CLL treated with lenalidomide-based regimens in the absence of thromboembolic prophylaxis is 2% to 6% (11) (12) (13) 24) . In this study, we observed VTE in 3 patients (9%). However, these patients had concomitant risk factors, suggesting that, even if thromboembolic prophylaxis during lenalidomide treatment may not be necessary, the concomitant use of pro-thrombotic agents should be avoided.
We performed a series of correlative biological studies to better understand the effects In our patients, treatment with ofatumumab and lenalidomide induced a significant decrease in plasma levels of bFGF and VEGF, confirming an activity of this treatment combination in the disruption of pro-angiogenic signals (12, 32) .
In conclusion, the combination of ofatumumab and lenalidomide is a feasible regimen that induces durable responses in the majority of patients with relapsed or refractory CLL and sustained MRD-negative CR in some. A higher number and preserved functional activity of NK-and T-cells were found in responding patients at baseline, as compared to NR, underscoring the importance of a competent immune system in supporting the effectiveness of this treatment and suggesting a need to further investigate these immune features as markers for prediction of response to therapy.
